Correlation of CpG island methylator phenotype with poor prognosis in hepatocellular carcinoma

Experimental and Molecular Pathology

Volumn 88, Issue 1, 2010, Pages 112-117

  Cheng, Yue ^a,b   Zhang, Changsong ^a,c   Zhao, Jun ^a   Wang, Chenyang ^a   Xu, Yun ^a   Han, Zhipeng ^a   Jiang, Guocheng ^a   Guo, Xianling ^a   Li, Rong ^a   Bu, Xinxin ^a   Wu, Mengchao ^a   Wei, Lixin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Department of Clinical Oncology   (China)

^c China   (China)

Author keywords

CIMP; Hepatocellular carcinoma; Methylation; Prognosis

Indexed keywords

DNA; GAMMA GLUTAMYLTRANSFERASE;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; GENETIC CORRELATION; GENETIC MARKER; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PROGNOSIS; PROMOTER REGION;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CPG ISLANDS; DNA METHYLATION; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PHENOTYPE; PROGNOSIS; PROMOTER REGIONS, GENETIC; SURVIVAL RATE;

EID: 74749090903     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2009.10.008     Document Type: Article

References (48)

1. Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., and Issa J.P. AlterationsIn DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 72 (1998) 141-196
2. Bilimoria M.M., Lauwers G.Y., Doherty D.A., Nagorney D.M., Belghiti J., Do K.A., Regimbeau J.M., Ellis L.M., Curley S.A., Ikai I., Yamaoka Y., Vauthey J.N., and International Cooperative Study Group on Hepatocellular Carcinoma. Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch. Surg. 136 (2001) 528-535
3. Chang M.S., Uozaki H., Chong J.M., Ushiku T., Sakuma K., Ishikawa S., Hino R., Barua R.R., Iwasaki Y., Arai K., Fujii H., Nagai H., and Fukayama M. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin. Cancer Res. 12 10 (2006) 2995-3002
4. Costello J.F., Frühwald M.C., Smiraglia D.J., Rush L.J., Robertson G.P., Gao X., Wright F.A., Feramisco J.D., Peltomäki P., Lang J.C., Schuller D.E., Yu L., Bloomfield C.D., Caligiuri M.A., Yates A., Nishikawa R., Su Huang H., Petrelli N.J., Zhang X., O'Dorisio M.S., Held W.A., Cavenee W.K., and Plass C. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. 24 (2000) 132-138
5. Darnton S.J., Hardie L.J., Muc R.S., Wild C.P., and Casson A.G. Tissue inhibitor of metalloproteinase-3 (TIMP-3) gene is methylated in the development of esophageal adenocarcinoma: loss of expression correlates with poor prognosis. Int. J. Cancer 115 (2005) 351-358
6. Eads C.A., Lord R.V., Wickramasinghe K., Long T.I., Kurumboor S.K., Bernstein L., Peters J.H., DeMeester S.R., DeMeester T.R., Skinner K.A., and Laird P.W. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 61 (2001) 3410-3418
7. Edmondson H.A., and Steiner P.E. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7 (1954) 462-503
8. El-Serag H.B. Hepatocellular carcinoma: an epidemiologic view. J. Clin. Gastroenterol. 35 (2002) S72-S78
9. Fiorentino M., Altimari A., D'Errico A., Cukor B., Barozzi C., Loda M., and Grigioni W.F. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin. Cancer Res. 6 (2000) 3966-3972
10. Goodman P.A., Burkhardt N., Juran B., Tibbles H.E., and Uckun F.M. Hypermethylation of the spleen tyrosine kinase promoter in T-lineage acute lymphoblastic leukemia. Oncogene 22 (2003) 2504-2514
11. Graziano F., Arduini F., Ruzzo A., Bearzi I., Humar B., More H., Silva R., Muretto P., Guilford P., Testa E., Mari D., Magnani M., and Cascinu S. Prognostic analysis of E-cadherin gene promoter hypermethylation inpatients with surgically resected, node-positive, diffuse gastric cancer. Clin. Cancer Res. 10 (2004) 2784-2789
12. Hawkins N., Norrie M., Cheong K., Mokany E., Ku S.L., Meagher A., O'Connor T., and Ward R. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 122 1 (2002) 376-387
13. Herman J.G., and Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349 (2003) 2042-2054
14. Herman J.G., Graff J.R., Myöhänen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 9821-9826
15. Honda K., Sbisà E., Tullo A., Papeo P.A., Saccone C., Poole S., Pignatelli M., Mitry R.R., Ding S., Isla A., Davies A., and Habib N.A. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br. J. Cancer 77 (1998) 776-782
16. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3 (2002) 415-428
17. Jones P.L., and Wolffe A.P. Relationships between chromatin organization and DNA methylation in determining gene expression. Semin. Cancer Biol. 9 (1999) 339-347
18. Kondoh N., Wakatsuki T., Hada A., Shuda M., Tanaka K., Arai M., and Yamamoto M. Genetic and epigenetic events in human hepatocarcinogenesis. Int. J. Oncol. 18 (2001) 1271-1278
19. Kwong J., Lo K.W., To K.F., Teo P.M., Johnson P.J., and Huang D.P. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res. 8 (2002) 131-137
20. Lai E.C., Fan S.T., Lo C.M., Chu K.M., Liu C.L., and Wong J. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann. Surg. 221 (1995) 291-298
21. Laird P.W. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3 (2003) 253-266
22. Latham K.E.X. Chromosome imprinting and inactivation in the early mammalian embryo. Trends Genet. 12 (1996) 134-138
23. Lee S., Lee H.J., Kim J.H., Lee H.S., Jang J.J., and Kang G.H. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am. J. Pathol. 163 (2003) 1371-1378
24. Liu L., Broaddus R.R., Yao J.C., Xie S., White J.A., Wu T.T., Hamilton S.R., and Rashid A. Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis. Mod. Pathol. 18 12 (2005) 1632-1640
25. Melki J.R., Vincent P.C., and Clark S.J. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res. 59 (1999) 3730-3740
26. Nosho K., Yamamoto H., Takahashi T., Mikami M., Hizaki K., Maehata T., Taniguchi H., Yamaoka S., Adachi Y., Itoh F., Imai K., and Shinomura Y. Correlation of laterally spreading type and JC virus with methylator phenotype status in colorectal adenoma. Hum. Pathol. 39 5 (2008) 767-775
27. Oue N., Mitani Y., Motoshita J., Matsumura S., Yoshida K., Kuniyasu H., Nakayama H., and Yasui W. Accumulation of DNA methylation is associated with tumor stage in gastric cancer. Cancer 106 (2006) 1250-1259
28. Poon R.T., Ng I.O., Lau C., Yu W.C., Yang Z.F., Fan S.T., and Wong J. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J. Clin. Oncol. 20 (2002) 1775-1785
29. Samowitz W.S., Albertsen H., Herrick J., Levin T.R., Sweeney C., Murtaugh M.A., Wolff R.K., and Slattery M.L. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 129 (2005) 837-845
30. Segditsas S., Sieber O.M., Rowan A., Setien F., Neale K., Phillips R.K., Ward R., Esteller M., and Tomlinson I.P. Promoter hypermethylation leads to decreased APC mRNA expression in familial polyposis and sporadic colorectal tumours, but does not substitute for truncating mutations. Exp. Mol. Pathol. 85 3 (2008) 201-206
31. Shaw R.J., Akufo-Tetteh E.K., Risk JM Field J.K., and Liloglou T. Methylation enrichment pyrosequencing: combining the specificity of MSP with validation by pyrosequencing. Nucleic. Acids Res. 34 11 (2006) 78 28
32. Shen L., Ahuja N., Shen Y., Habib N.A., Toyota M., Rashid A., and Issa J.P. DNA methylation and environmental exposures in human hepatocellular carcinoma. J. Natl. Cancer Inst. 94 (2002) 755-761
33. Shen L., Toyota M., Kondo Y., Lin E., Zhang L., Guo Y., Hernandez N.S., Chen X., Ahmed S., Konishi K., Hamilton S.R., and Issa J.P. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl. Acad. Sci. U. S. A. 104 47 (2007) 18654-18659 20
34. Tanemura A., Terando A.M., Sim M.S., van Hoesel A.Q., de Maat M.F., Morton D.L., and Hoon D.S. CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res. 15 5 (2009) 1801-1807
35. Toyota M., Ahuja N., Ohe-Toyota M., Herman J.G., Baylin S.B., and Issa J.P. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 8681-8686
36. Toyota M., Ahuja N., Suzuki H., Itoh F., Ohe-Toyota M., Imai K., Baylin S.B., and Issa J.P. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 59 (1999) 5438-5442
37. Vauthey J.N., Klimstra D., Franceschi D., Tao Y., Fortner J., Blumgart L., and Brennan M. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am. J. Surg. 169 (1995) 28-34
38. Vauthey J.N., Lauwers G.Y., Esnaola N.F., Do K.A., Belghiti J., Mirza N., Curley S.A., Ellis L.M., Regimbeau J.M., Rashid A., Cleary K.R., and Nagorney D.M. Simplified staging for hepatocellular carcinoma. J. Clin. Oncol. 20 (2002) 1527-1536
39. Weisenberger D.J., Siegmund K.D., Campan M., Young J., Long T.I., Faasse M.A., Kang G.H., Widschwendter M., Weener D., Buchanan D., Koh H., Simms L., Barker M., Leggett B., Levine J., Kim M., French A.J., Thibodeau S.N., Jass J., Haile R., and Laird P.W. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 38 (2006) 787-793
40. Wong I.H., Lo Y.M., Yeo W., Lau W.Y., and Johnson P.J. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin. Cancer Res. 6 9 (2000) 3516-3521
41. Yamamoto M., Takasaki K., Otsubo T., Katsuragawa H., Katagiri S., Yoshitoshi K., Ariizumi S., Saito A., and Nakano M. Favorable surgical outcomes in patients with early hepatocellular carcinoma. Ann. Surg. 239 (2004) 395-399
42. Yamashita K., Dai T., Dai Y., Yamamoto F., and Perucho M. Genetics supersedes epigenetics in colon cancer phenotype. Cancer Cell 4 (2003) 121-131
43. Yeo W., and Mok T.S. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl. Cancer Inst. 97 (2005) 1532-1538
44. Yoo H.Y., Patt C.H., Geschwind J.F., and Thuluvath P.J. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J. Clin. Oncol. 21 (2003) 4329-4335
45. Yuan Y., Mendez R., Sahin A., and Dai J.L. Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Res. 61 (2001) 5558-5561
46. Yuan Y., Wang J., Li J., Wang L., Li M., Yang Z., Zhang C., and Dai J.L. Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma. Clin. Cancer Res. 12 22 (2006) 6687-6695
47. Yu J., Zhang H.Y., Ma Z.Z., Lu W., Wang Y.F., and Zhu J.D. Methylation profiling of twenty four genes and the concordant methylation behaviors of nineteen genes that may contribute to hepatocellular carcinogenesis. Methylation profiling of twenty four genes and the concordant methylation behaviors of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell Res. 13 (2003) 319-333
48. Zhang C., Li Z., Cheng Y., Jia F., Li R., Wu M., Li K., and Wei L. CpG island methylator phenotype association with elevated serum alpha-fetoprotein level in hepatocellular carcinoma. Clin. Cancer Res. 13 3 (2007) 944-952